Small Molecules

LY364947

Activin/BMP/TGF-β pathway inhibitor;
Inhibits ALK5

Catalog # 72592

5 mg

STEMCELL™ TECHNOLOGIES
Scientists Helping Scientists™ | WWW.STEMCELL.COM
TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713
INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM
FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

LY364947 is a selective inhibitor of Activin/NODAL/TGF-β pathway that inhibits ALK5 (Sawyer et al.). Transforming growth factor-beta (TGF-β) superfamily ligands signal through a cell surface heteromeric complex involving type I (TGFβRI) and type II (TGFβRII) receptors. Downstream signal transduction is mediated by the TGFβRI kinase domain through the phosphorylation of SMAD proteins. LY364947 is a selective inhibitor of the TGFβRI ALK5 (IC_{50} = 59 nM; Sawyer et al.). LY364947 less effectively inhibits TGFβRII (IC_{50} = 400 nM), p38 MAPK (IC_{50} = 740 nM), and mixed lineage kinase-7 (MLK-7; IC_{50} = 1,400 nM; Li et al. 2006; Sawyer et al.).

Molecular Name:	LY364947
Alternative Names:	E-616451; HTS 466284; TGF-β RI Kinase Inhibitor
CAS Number:	396129-53-6
Chemical Formula:	$C_{17}H_{12}N_4$
Molecular Weight:	272.3 g/mol
Purity:	≥ 98%
Chemical Name:	4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline
Structure:	

Properties

Physical Appearance:	A crystalline solid
Storage:	Product stable at -20°C as supplied. Protect from prolonged exposure to light. Stable as supplied for 12 months from date of receipt.
Solubility:	· DMSO ≤ 3.6 mM For example, to prepare a 1 mM stock solution in DMSO, resuspend 1 mg in 3.67 mL of fresh DMSO. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

REPROGRAMMING
· In combination with Valproic Acid (Catalog #72292), can replace SOX2 in reprogramming of mouse embryonic fibroblasts transduced with OCT4, KLF4 and c-MYC (Ichida et al.).
DIFFERENTIATION
· Blocks chondrogenesis induced by mechanical load in human mesenchymal stem cells (Li et al. 2010).
· Restores the hematopoietic potential of mouse para-aortic splanchnopleural cells deficient for the Evi-1 transcription factor (Sato et al.).
· Impairs definitive endoderm differentiation competence in human embryonic stem (ES) cells (Jaremko et al.).
· Blocks TGF-β-induced endothelial-to-mesenchymal transition of NMuMg mammary epithelial cells or mouse ES cell-derived endothelial cells (Peng et al.; Kokudo et al.).
CANCER RESEARCH
· Suppresses colony-forming ability of mouse and human leukemia-initiating cells cultured with OP-9 stromal cells, and, when combined with Imatinib (Catalog #72532), reduces lethality in a mouse model of chronic myeloid leukemia (Naka et al.).
· Reduces invasiveness of MDA-MB-231 breast cancer cells in a Matrigel invasion assay (Shiou et al.).

References

Ichida JK et al. (2009) A small-molecule inhibitor of TGF-beta signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell 5(5): 491–503.
Jaremko KL & Marikawa Y. (2013) Regulation of developmental competence and commitment towards the definitive endoderm lineage in human embryonic stem cells. Stem Cell Res 10(3): 489–502.
Kokudo T et al. (2008) Snail is required for TGFbeta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 121(20): 3317–24.
Li H et al. (2006) Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7. J Med Chem 49(6): 2138–42.
Li Z et al. (2010) Mechanical load modulates chondrogenesis of human mesenchymal stem cells through the TGF-beta pathway. J Cell Mol Med 14(6A): 1338–46.
Naka K et al. (2010) TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463(7281): 676–80.
Peng S-B et al. (2005) Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 44(7): 2293–304.
Sato T et al. (2008) Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-b signaling. Cancer Sci 99(7): 1407–13.
Sawyer JS et al. (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem 46(19): 3953–6.
Shiou S-R et al. (2006) Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J Biol Chem 281(45): 33971–81.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, visit www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

This product is hazardous. Please refer to the Safety Data Sheet (SDS).